Lilly Marks Major Milestone for Mirror Portfolio
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that the Mirror Portfolio, a concept created by Lilly to access innovation being developed outside the company's walls, has achieved a significant milestone.
First African country introduces GSK's pneumococcal vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneumococcal vaccines through the innovative financing mechanism known as the Advance Market Commitment (AMC),
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement
- Details
- Category: Boehringer Ingelheim
Elan plc (NYSE: ELN) and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
Sanofi-aventis' fourth-quarter and full-year net sales
- Details
- Category: Sanofi
In the fourth quarter of 2010, sanofi-aventis generated net sales of €7,395 million, up 0.5% on a reported basis. Exchange rate movements had a favorable effect of 6.4 percentage points, mainly due to the weaker euro versus the U.S. dollar, Japanese Yen, Brazilian Real, and Australian dollar.
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
- Details
- Category: Novartis
The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
- Details
- Category: Bayer
Bayer HealthCare announced that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).
More Pharma News ...
- Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
- GSK revises US Avandia label to include new restrictions on use
- Pfizer To Acquire Ferrosan's Consumer Healthcare Business
- Nycomed to acquire Colombian company Farmacol
- New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
- GSK's full year trading update
- The Roche Group posted solid overall results in 2010